Product
Nivolumab + Relatlimab
Aliases
BMS-986213, Nivolumab 240 mg / Relatlimab 80 mg in a fixed dose combination, nivolumab + relatlimab, Opdualag (1 other aliases)
Name
OPDUALAG
FDA Approved
Yes
14 clinical trials
1 organization
2 drugs
25 indications
1 document
Indication
MelanomaIndication
Metastatic Uveal Melanoma in the LiverIndication
Renal Cell CarcinomaIndication
Bladder CancerIndication
Solid TumorIndication
Hepatocellular CarcinomaIndication
Lung CancerIndication
Colorectal CancerIndication
Head and Neck Squamous Cell CarcinomaIndication
CancerIndication
Metastatic MelanomaIndication
Brain MetastasisIndication
Cutaneous Squamous Cell CarcinomaIndication
Skin Squamous Cell CarcinomaIndication
Merkel Cell CarcinomaIndication
Cutaneous Melanoma AJCC v8Indication
Cutaneous MelanomaIndication
Cutaneous Melanoma (Clinical Stage IB)Indication
Stage IV Cutaneous MelanomaIndication
Melanoma stage IIIIndication
melanomaIndication
Soft Tissue SarcomaIndication
Advanced CancerDrug
RelatlimabClinical trial
A Phase 3 Randomized, Controlled Study of IMC-F106C Plus Nivolumab Versus Nivolumab Regimens in HLA-A*02:01-Positive Participants With Previously Untreated Advanced Melanoma (PRISM-MEL-301Status: Recruiting, Estimated PCD: 2026-12-01
Clinical trial
Randomized, Ph3 Clinical Study Comparing Vusolimogene Oderparepvec in Combination With Nivolumab Vs Treatment of Physician's Choice in Patients With Advanced Melanoma That Progressed on Anti-PD-1 and Anti-CTLA-4 Containing TreatmentStatus: Not yet recruiting, Estimated PCD: 2029-01-01
Clinical trial
A Phase 1/1b, Open-Label Study of the Pressure-Enabled Hepatic Artery Infusion of SD-101, a TLR9 Agonist, Alone or in Combination With Intravenous Checkpoint Blockade in Adults With Metastatic Uveal MelanomaStatus: Active (not recruiting), Estimated PCD: 2024-09-01
Clinical trial
A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination With Immuno-Oncology Agents in Subjects With Unresectable Advanced or Metastatic Solid TumorsStatus: Recruiting, Estimated PCD: 2026-02-01
Clinical trial
Pan-Tumor Study for Long-term Treatment of Cancer Patients Who Have Participated in BMS Sponsored Trials Investigating Nivolumab and Other Cancer TherapiesStatus: Recruiting, Estimated PCD: 2029-08-25
Clinical trial
A Phase 3, Randomized, Double-blind Study of Adjuvant Immunotherapy With Nivolumab + Relatlimab Fixed-dose Combination Versus Nivolumab Monotherapy After Complete Resection of Stage III-IV MelanomaStatus: Active (not recruiting), Estimated PCD: 2026-02-15
Clinical trial
A Phase 3, Randomized, Open-label, Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination Versus Intravenous Nivolumab + Relatlimab Fixed-dose Combination in Participants With Previously Untreated Metastatic or Unresectable MelanomaStatus: Recruiting, Estimated PCD: 2025-02-28
Clinical trial
A Randomized, Pilot Study to Evaluate the Molecular and Cellular Response to Treatment With Nivolumab With Either Adjuvant Ipilimumab or Relatlimab in Adult Patients With Surgically Resectable Melanoma Brain MetastasesStatus: Active (not recruiting), Estimated PCD: 2027-01-01
Clinical trial
A Phase 2, Open Label, Single Arm, Clinical Trial of Neoadjuvant Nivolumab and Relatlimab in Stage II To IV Resectable Cutaneous Squamous Cell CarcinomaStatus: Not yet recruiting, Estimated PCD: 2026-06-01
Clinical trial
Phase II Study of Nivolumab (Group 1) and Nivolumab Plus Relatlimab (Group 2) in Patients With Locally Advanced/ Metastatic Squamous Cell Carcinoma of the SkinStatus: Recruiting, Estimated PCD: 2026-12-01
Clinical trial
A Phase 2, Open Label, Single Arm Clinical Trial of Neoadjuvant Nivolumab and Relatlimab in Stage I To III Resectable Merkel Cell CarcinomaStatus: Recruiting, Estimated PCD: 2026-04-01
Clinical trial
Intralesional Influenza Vaccine for Patients With MelanomaStatus: Recruiting, Estimated PCD: 2023-12-31
Clinical trial
Biomarker Driven Patient Selection for Neoadjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma: A Pilot StudyStatus: Recruiting, Estimated PCD: 2027-03-01
Clinical trial
Combination of Nivolumab Plus Relatlimab in Patients With Advanced or Metastatic Soft-tissue Sarcoma: a Proof-of-concept Randomized Phase II Study.Status: Recruiting, Estimated PCD: 2024-06-01
Document
DailyMed Label: OPDUALAGOrganization
E.R. Squibb & Sons, L.L.C.